MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

Search

Neogen Corp

Fermé

SecteurSoins de santé

9.27 3.92

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.91

Max

9.28

Chiffres clés

By Trading Economics

Revenu

-52M

-16M

Ventes

16M

225M

Marge bénéficiaire

-7.087

Employés

2,974

EBITDA

-66M

23M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+23.46% upside

Dividendes

By Dow Jones

Prochains Résultats

9 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

361M

1.9B

Ouverture précédente

5.35

Clôture précédente

9.27

Sentiment de l'Actualité

By Acuity

50%

50%

148 / 349 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Neogen Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 mars 2026, 23:31 UTC

Actions en Tendance

Stocks to Watch: Nike, RH, NCino

31 mars 2026, 22:35 UTC

Résultats

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 avr. 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mars 2026, 23:50 UTC

Acquisitions, Fusions, Rachats

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mars 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mars 2026, 23:33 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mars 2026, 23:21 UTC

Résultats

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mars 2026, 23:14 UTC

Market Talk
Résultats

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mars 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Loss Widens >000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mars 2026, 21:46 UTC

Acquisitions, Fusions, Rachats

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mars 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mars 2026, 21:35 UTC

Résultats

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mars 2026, 21:35 UTC

Résultats

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mars 2026, 21:35 UTC

Résultats

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mars 2026, 21:33 UTC

Acquisitions, Fusions, Rachats

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mars 2026, 21:33 UTC

Résultats

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mars 2026, 21:32 UTC

Résultats

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mars 2026, 21:28 UTC

Résultats

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mars 2026, 21:26 UTC

Résultats

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mars 2026, 21:25 UTC

Résultats

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mars 2026, 21:24 UTC

Market Talk
Résultats

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mars 2026, 21:22 UTC

Résultats

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mars 2026, 21:22 UTC

Résultats

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mars 2026, 21:21 UTC

Résultats

Nike's Digital Channel Still Too Promotional, CFO Says

31 mars 2026, 21:20 UTC

Résultats

Nike CEO: Converse Remains Important to Portfolio

Comparaison

Variation de prix

Neogen Corp prévision

Objectif de Prix

By TipRanks

23.46% hausse

Prévisions sur 12 Mois

Moyen 11 USD  23.46%

Haut 12 USD

Bas 10 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

1

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

5.17 / 5.99Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

148 / 349Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Neogen Corp

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared food products and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. The company was incorporated in 1981 and is headquartered in Lansing, Michigan.
help-icon Live chat